Jane Street
ENTA icon

Jane Street’s Enanta Pharmaceuticals ENTA Stock Holding History

Jane Street’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-44,900
Closed -$537K – 11427
2025
Q3 		$537K Buy
+44,900
New +$359K ﹤0.01% 7703
2023
Q1 		– Sell
-6,200
Closed -$288K – 9237
2022
Q4 		$288K Sell
6,200
-11,800
-66% -$538K ﹤0.01% 7085
2022
Q3 		$934K Buy
18,000
+1,800
+11% +$105K ﹤0.01% 5522
2022
Q2 		$766K Buy
+16,200
New +$879K ﹤0.01% 5971
2021
Q4 		– Sell
-11,100
Closed -$631K – 10236
2021
Q3 		$631K Buy
+11,100
New +$549K ﹤0.01% 6839

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street's ENTA Position: Q4 2025 in Review

Jane Street sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 19,165 shares — an estimated $229K sold.

Jane Street first reported a position in ENTA in Q2 2014 and held it in 22 quarters. The position peaked at $1.61M in Q3 2023. 132 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

  • Jane Street reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 19,165 Enanta Pharmaceuticals shares in Q4 2025, an estimated $229K.
  • Jane Street first reported a position in Enanta Pharmaceuticals in Q2 2014 and held it in 22 quarters.
  • Jane Street's Enanta Pharmaceuticals position peaked at $1.61M in Q3 2023.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.